Compare Coherent (COHR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Coherent Corp. (COHR) trades at $317.36, up 9.46% on the day, reflecting strong momentum driven by AI datacenter demand. The stock exhibits a bullish technical trend, with recent earnings beats and a consensus analyst price target of $390.38 suggesting significant upside. Revenue growth is accelerating, with Q4 2025 sales reaching $2.05 billion, though high valuation ratios like a P/E of 71.84 indicate a premium price for future growth expectations.

The outlook is positive, supported by robust AI infrastructure demand and expanding product portfolios, but risks include execution challenges from heavy capital expenditure and a premium valuation that leaves the stock vulnerable to negative news. Investor sentiment is overwhelmingly bullish among analysts, with 81% recommending a buy.

Regeneron Pharmaceuticals (REGN) trades at $784.85, up 1.32% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $14.29 surpassing expectations of $10.16. Financials show robust profitability, including a gross margin of 84.86% and net income margin of 27.86% for 2025. Recent news highlights growth catalysts for Dupixent and EYLEA HD, alongside a securities class action lawsuit related to a Phase 3 trial disclosure.

Outlook remains positive with analyst consensus price target of $827.71, implying ~5% upside, supported by 69% buy ratings. Key opportunities include pipeline advancements and revenue growth, but risks involve legal uncertainties and competitive pressures in biopharma. Investors should weigh strong fundamentals against litigation headwinds for near-term performance.